Skip to content

Experimental and Clinical Psychopharmacology

ISSN 1064-1297, 1936-2293

40 papers in the library · 501 citations · publishing 1997-2026

Papers

Sort Most recent Most cited

The influence of acute cannabis smoking on cigarette and e-cigarette puff topography and subjective effects in people who use cannabis, cigarettes, and e-cigarettes.

Experimental and Clinical Psychopharmacology October 22, 2026 C Austin Zamarripa, Tory R Spindle, Dustin C Lee et al.

Co-use of smoked/vaped tobacco and cannabis is increasing with expanding legalization, yet controlled clinical studies examining mechanisms underlying co-use remain limited. This study evaluated whether acute smoked cannabis influences subsequent use ("chasing") of combustible cigarettes and e-cigarettes among people who use cannabis, cigarettes, and e-cigarettes. Twenty adults who used...

Self-reported changes and experiences with substance use among real-world patients treated with medical ketamine.

Experimental and Clinical Psychopharmacology July 24, 2025 Shahar Almog, Maribel Rodriguez Perez, Deepthi S Varma et al.

Ketamine is increasingly used in community clinics as a long-term treatment for different psychiatric and pain conditions, including substance use disorders. Data are lacking, however, regarding the potential influence of ketamine on other substance use. In this secondary analysis, we aimed to explore the relationship between medical ketamine and other substance use among real-world patients by...

DOI: 10.1037/pha0000788 (opens in new tab) Full text (opens in new tab) Ketamine therapy Medical ketamine Psychiatric ketamine Ketamine treatment +16

Differential effects of repeated fluoxetine and ketamine administration on behavioral and pharmacological stressor-induced depression of digging behavior in mice.

Experimental and Clinical Psychopharmacology October 1, 2024 Kaitlyn J Partridge, Todd M. Hillhouse 1 citation

Major depressive disorder is a multifactorial disorder that originates from a complex web of variables and overlaps with similar disorders (e.g., depression and anxiety). As such, animal models should account for the considerable symptom overlap between psychiatric disorders. We sought to extend the findings of behavioral assays that encompass both anxiety and stress/depression components. To...

DOI: 10.1037/pha0000711 (opens in new tab) Full text (opens in new tab) Antidepressants Stress response Personalized medicine Psychiatric treatment +1

Baseline affective symptomatology moderates acute subjective effects of high potency THC and CBD cannabis concentrates.

Experimental and Clinical Psychopharmacology December 2023 Renée Martin-Willett, Carillon J. Skrzynski, Hollis C Karoly et al.

Highly potent cannabis concentrates are widely available and associated with affective disturbance and cannabis use disorder. Little is known about the effects of concentrated Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and their relationship to long-term affect. We explored how baseline affective symptoms (anxiety and depression) relate to acute (i.e., immediate or short-term)...

Call for evidence-based psychedelic integration.

Experimental and Clinical Psychopharmacology November 27, 2023 Jakub Greń, Ingmar Gorman, Anastasia Ruban et al. 27 citations

The use of psychedelics for various purposes was common in different civilizations throughout human history and has been explored scientifically for more than a century. Although the applications of psychedelics show promise in the treatment of various psychiatric and neurological indications, as well as in facilitation of well-being and personal growth, several psychedelic-related risks and...

Changing the paradigm in treatment-resistant depression: A review of long-term efficacy and tolerability of esketamine nasal spray.

Experimental and Clinical Psychopharmacology May 1, 2023 Jesús Herrera-Imbroda

Treatment-resistant depression (TRD) is a major public health problem worldwide. There are currently five strategies for its treatment: optimization, change, combination, augmentation, and somatic therapies. However, many of these therapies are not fully effective, are not accessible, or have a significant number of side effects. Esketamine nasal spray has recently been approved, in combination...

Conditioned anti-immobility by ketamine: A comparison to escitalopram and bupropion.

Experimental and Clinical Psychopharmacology April 1, 2023 Brett Melanson, Michael Wolter, Zion Leatham et al.

This study was designed to explore the clinical belief that "set and setting" play an important role in favorable responses to psychedelic agents such as ketamine (KET). In fact, there is evidence in animals that the antidepressant effect of this drug may involve drug-environment interactions in which a context paired with its effects acquires the ability to influence behavior. Therefore, it...

Effect of cannabinoids on brain metabolites: A review of animal and human studies.

Experimental and Clinical Psychopharmacology February 2023 Jiyoung Ma, In Kyoon Lyoo, Perry F Renshaw et al.

Cannabis has been widely used medically and recreationally for centuries. With a renewed interest in the therapeutic use of cannabinoids, which are active components of Cannabis sativa, it has become important to understand the cannabinoids' neurobiological mechanisms related to both therapeutic and harmful effects. This review summarizes the effects of two major cannabinoids,...

Interoceptive attention or merely distraction? An examination of the effects of brief breath counting training on stress-induced alcohol-seeking behavior.

Experimental and Clinical Psychopharmacology February 1, 2023 Luke Herchenroeder, Eleanor Williams, Emma Wedell et al.

Prior research suggests brief mindfulness (breath counting) interventions may be effective at attenuating stress-induced alcohol-related cravings. However, it remains unclear whether this reduction in craving is due to increased state mindfulness or mere distraction. To test this, the present study examined whether brief breath counting would attenuate a stress-induced increase in the relative...

Meditation trips: A thematic analysis of the combined naturalistic use of psychedelics with meditation practices.

Experimental and Clinical Psychopharmacology December 19, 2022 Kiana Azmoodeh, Emily Thomas, Sunjeev K. Kamboj

Similarities between meditative and psychedelic states have long been recognized. Recently, parallels in the psychological mechanisms mediating the beneficial effects of mindfulness and psychedelic treatments-as well as their potential therapeutic complementarity-have been noted. However, empirical research in this area remains limited. Here, we explore the naturalistic use of meditation...

DOI: 10.1037/pha0000617 (opens in new tab) Full text (opens in new tab) Meditation Humans Substance withdrawal syndrome Hallucinogens +1

Impact of fluoxetine preexposure on MDMA-induced taste avoidance in male and female rats.

Experimental and Clinical Psychopharmacology November 17, 2022 Sara K Bowman, Shihui Huang, Marissa E Vasquez et al.

The use of both prescription and illicit drugs creates the potential for drug interactions as a function of both pharmacokinetic and pharmacodynamic processes. One such interaction is that of fluoxetine and methylenedioxymethamphetamine (MDMA) in which fluoxetine attenuates the positive-like effects of MDMA. The present work extends the analysis of their interaction by examining the impact of...

DOI: 10.1037/pha0000610 (opens in new tab) Full text (opens in new tab) Animals Rats, sprague-dawley N-methyl-3,4-methylenedioxyamphetamine Fluoxetine +3

To treat or not to treat? High-potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder.

Experimental and Clinical Psychopharmacology September 1, 2022 Julie A E Christensen, David C. Fipps, J Michael Bostwick 4 citations

Hallucinogen persisting perception disorder (HPPD) is characterized by visual disturbances that resemble psychedelic intoxication and linger after use has ceased. The most common substances precipitating HPPD, lysergic acid diethylamide (LSD) and psilocybin, are posited to do so via damage to serotonergic neurons involved in vision. Mr. N is a 37-year-old with a history of alcohol, cannabis,...

Harmine impairs memory performance of treated rats and nontreated cagemates.

Experimental and Clinical Psychopharmacology November 4, 2021 Tânia Cristina Libânio, R. Eufrásio, Suzy S Niigaki et al. 6 citations

The interest in psychedelic substances as potential treatments for psychiatric disorders is increasing. The β-carboline harmine, an Ayahuasca component, presents hallucinogenic and antidepressant effects. Although Ayuahuasca-and consequently harmine-is usually consumed in rituals, the role of social contexts in the behavioral effects of harmine has not been investigated yet. In this sense,...

Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.

Experimental and Clinical Psychopharmacology June 7, 2021 Colleen Fogg, Timothy I. Michaels, Sara de la Salle et al. 53 citations

Emerging evidence from randomized, double-blind, placebo-controlled clinical trials suggests psychedelic compounds such as 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and lysergic acid diethylamide (LSD), when administered as an adjunct to psychotherapy, that is, psychedelic-assisted psychotherapy (PAP), may be beneficial for treating substance use disorders, posttraumatic stress...

DOI: 10.1037/pha0000490 (opens in new tab) Psychotherapist Clinical psychology

Cognitive outcomes associated with long-term, regular, recreational cannabis use in adults: A meta-analysis.

Experimental and Clinical Psychopharmacology August 1, 2020 M. Lovell, Jane Akhurst, C. Padgett et al.

Despite research advances, it remains unclear if long-term, regular cannabis use harms cognition once intoxication has passed. Our meta-analysis aimed to investigate the association between cognitive functioning and long-term (mean ≥2 years), regular (mean ≥4 days/week), recreational cannabis use in adults during abstinence (mean ≥12 hr). We searched PubMed, PsycINFO, CINAHL, Scopus, and...

Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.

Experimental and Clinical Psychopharmacology January 10, 2019 Farhana Sakloth, Elizabeth Leggett, Megan J. Moerke et al. 42 citations

The prototype 5-HT2A receptor agonist hallucinogens LSD, mescaline, and psilocybin are classified as Schedule 1 drugs of abuse by the U.S. Drug Enforcement Administration. Accumulating clinical evidence has also suggested that acute or repeated "microdosing" with these drugs may have utility for treatment of some mental health disorders, including drug abuse and depression. The goal of the...

Previous cannabis exposure modulates the acute effects of delta-9-tetrahydrocannabinol on attentional salience and fear processing.

Experimental and Clinical Psychopharmacology December 2018 Marco Colizzi, Philip Mcguire, Vincent Giampietro et al.

Cannabis can induce transient psychotic and anxiety symptoms and long-lasting disorders. The acute psychoactive effects of its main active ingredient, (-)-trans-Δ9-tetrahydrocannabinol (Δ9-THC), may be modulated by previous cannabis exposure. Secondary data analyses tested whether modest previous cannabis exposure modulated the acute effects of Δ9-THC on attentional salience and emotional...

Autonomic and affective mediators of the relationship between mindfulness and opioid craving among chronic pain patients.

Experimental and Clinical Psychopharmacology September 27, 2018 Anne Baker, Eric L Garland

Prescription opioid misuse among chronic pain patients is undergirded by self-regulatory deficits, affective distress, and opioid-cue reactivity. Dispositional mindfulness has been associated with enhanced self-regulation, lower distress, and adaptive autonomic responses following drug-cue exposure. We hypothesized that dispositional mindfulness might serve as a protective factor among...

Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) and R(-) MDMA on actigraphy-based daytime activity and sleep parameters in rhesus monkeys.

Experimental and Clinical Psychopharmacology June 25, 2018 Lais Fernanda Berro, Hannah Shields, Melis Odabas-Geldiay et al. 6 citations

(-) MDMA (0.3, 1.0, or 1.7 mg/kg) at 9 or 16 h (3 h before "lights off"). Morning treatments had no effects on sleep-like parameters. Racemic MDMA decreased general daytime activity during the first hour after injection and increased daytime activity at 3 hr posttreatment. Although afternoon administration of racemic MDMA increased sleep latency, it improved other sleep parameters, decreasing...

Influence of tiagabine maintenance on cannabis effects and related behaviors in daily cannabis users.

Experimental and Clinical Psychopharmacology June 2018 Michael J Wesley, Philip M Westgate, William W Stoops et al.

No medications are approved for cannabis use disorder (CUD). Gamma-aminobutyric acid (GABA) reuptake is modulated by cannabinoid (CB) receptor agonists, and there are shared effects between CB agonists and the GABA reuptake inhibitor tiagabine. This overlapping neuropharmacology suggested that tiagabine might be useful for CUD. The study determined the ability of tiagabine maintenance to reduce...

An assessment of concurrent cannabidiol and Δ⁹-tetrahydrocannabinol administration in place aversion and taste avoidance conditioning.

Experimental and Clinical Psychopharmacology April 2018 Briana J. Hempel, Matthew M Clasen, Katharine H Nelson et al.

Rising interest in medical marijuana has prompted research into its phytocannabinoid constituents, particularly Δ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD). Coadministration of CBD with THC has been shown to modulate a number of THC's effects, including its negative stimulus properties (e.g., anxiety, paranoia, psychosis) in a clinical setting. The present series of experiments extended...

Effects of NMDA antagonists ketamine, methoxetamine and phencyclidine on the odor span test of working memory in rats

Experimental and Clinical Psychopharmacology February 1, 2018 Michael Mathews, R. N. Mead, M. Galizio

The glutamate hypothesis proposes that N-Methyl-D-aspartate (NMDA) receptor hypofunction underlies cognitive and perhaps other schizophrenic symptoms. The present study used the odor span task to assess the effects of NMDA antagonists on remembering multiple stimuli in rodents. This task uses an incrementing nonmatching-to-sample procedure in which responses to a new olfactory stimulus are...

Altered subjective reward valuation among female heavy marijuana users.

Experimental and Clinical Psychopharmacology February 2017 Kathryn R. Hefner, Mark. J. Starr

Maladaptive decision-making is a cardinal feature of drug use, contributing to ongoing use, and reflecting alterations in how drug users assess uncertain reward value. Accumulating evidence indicates the consequences of heavy marijuana use are worse for female versus male animals and humans, but research assessing sex differences in reward-related decision-making among marijuana users remains...

Clinical applications of hallucinogens: A review.

Experimental and Clinical Psychopharmacology August 1, 2016 Albert Garcia‐romeu, Brennan Kersgaard, Peter H. Addy 198 citations

Hallucinogens fall into several different classes, as broadly defined by pharmacological mechanism of action, and chemical structure. These include psychedelics, entactogens, dissociatives, and other atypical hallucinogens. Although these classes do not share a common primary mechanism of action, they do exhibit important similarities in their ability to occasion temporary but profound...